Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms

Area of Science:

• Epigenetics
• Hematology
• Oncology

Background:

• Epigenetic dysregulation is implicated in myeloproliferative neoplasms (MPNs) pathogenesis.
• Ruxolitinib, a JAK/STAT inhibitor, is used for MPNs but has limited disease-modifying capacity.

Purpose of the Study:

• To investigate the impact of JAK inhibition by ruxolitinib on the histone modification landscape in MPN cell lines and patient samples.
• To correlate observed epigenetic changes with gene expression alterations.

Main Methods:

• Histone modification assays and chromatin immunoprecipitation sequencing (CHIP-seq) were performed on MPN cell line models.
• RNA sequencing was used to assess gene expression changes.
• Analysis included samples from the MAJIC clinical trial of ruxolitinib in polycythaemia vera and essential thrombocythaemia.

Main Results:

• Ruxolitinib demonstrated an epigenetic modifying effect, upregulating most histone H3 modifications, notably H3K27me3 and H3K36me2.
• CHIP-seq revealed increased H3K4me3 and H3K27ac peaks at promoter regions, indicating active transcription.
• RNA sequencing showed a coordinated reduction in gene expression across pathways like PI3K-AKT and JAK-STAT signaling, despite histone changes.

Conclusions:

• Ruxolitinib induces significant alterations in the histone landscape of MPN cells.
• The complex interplay between histone modifications and gene expression highlights intricate transcriptional control mechanisms in MPNs.
• Further research is needed to fully elucidate the therapeutic potential of JAK inhibitors in modifying MPN epigenetics.